Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | RXRA | P19793 | 5/20 | 0.56 |
| ▸ | RXRB | P28702 | 4/20 | 0.56 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | RARB | P10826 | 3/20 | 0.50 |
| ▸ | RXRG | P48443 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzoic Acid SCHEMBL4541255 | 0.89 | NR4A2 (0.53) | ALDH1A1RXRARXRBPLA2G4BSMN1; SMN2 | |
| SCHEMBL1750568 | 0.89 | PLA2G4B (0.63) | ALDH1A1RXRARXRBPLA2G4BNPC1 | |
| SCHEMBL1749669 | 0.88 | PLA2G4B (0.65) | ALDH1A1PLA2G4BRARBTP53TSHR | |
| SCHEMBL15153312 | 0.86 | PLA2G4B (0.67) | ALDH1A1PLA2G4BRARBTP53TSHR | |
| SCHEMBL9321559 | 0.86 | PLA2G4B (0.67) | ALDH1A1PLA2G4BRARBTP53TSHR | |
| Terephthalic Acid SCHEMBL5179959 | 0.86 | RARB (0.57) | ALDH1A1PLA2G4BSMN1; SMN2RARBTP53 | |
| SCHEMBL1749635 | 0.85 | ALDH1A1 (0.61) | ALDH1A1RXRARXRBPLA2G4BNPC1 | |
| SCHEMBL9439348 | 0.84 | ALDH1A1 (0.69) | ALDH1A1RXRARXRBNPC1POLB | |
| SCHEMBL8067972 | 0.84 | RARB (0.65) | ALDH1A1PLA2G4BRARBTP53TSHR | |
| SCHEMBL8051888 | 0.84 | ALDH1A1 (0.43) | ALDH1A1RXRARXRBPLA2G4BNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103420824-B | Preparation method of alkoxy methyl benzoic acid | YANTAI VALIANT FINE CHEMICALS CO LTD | 2015-06-17 | — | — | CN | disclosed |
| CN-103420824-A | Preparation method of alkoxy methyl benzoic acid | YANTAI VALIANT FINE CHEMICALS CO LTD | 2013-12-04 | — | — | CN | disclosed |
| US-8466199-B2 | Allyloxy and alkyloxy benzoic acid delivery agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466199-B2 | Allyloxy and alkyloxy benzoic acid delivery agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466199-B2 | Allyloxy and alkyloxy benzoic acid delivery agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-7968550-B2 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| US-20100105604-A1 | ALLYLOXY AND ALKYLOXY BENZOIC ACID DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100105604-A1 | ALLYLOXY AND ALKYLOXY BENZOIC ACID DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100105604-A1 | ALLYLOXY AND ALKYLOXY BENZOIC ACID DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| EP-2136624-A1 | ALLYLQXY AND ALKYLOXY BENZOIC ACID DELIVERY AGENTS | Emisphere Technologies, Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008116141-A1 | ALLYLQXY AND ALKYLOXY BENZOIC ACID DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7223788-B2 | therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| EP-1597228-A2 | SUBSTITUTED N-ARYLHETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
| WO-2004072025-A2 | SUBSTITUTED N-ARYLHETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | WO | disclosed |
| EP-1010687-A2 | Ester derivative, liquid crystal composition and liquid crystal display element | Chisso Corporation (JP) | 2000-06-21 | — | — | EP | disclosed |
| US-5755994-A | LARGE DIELECTRIC ANISOTROPIC | CHISSO CORPORATION (JP) | 1998-05-26 | — | — | US | disclosed |
| CN-1136067-A | Liquid crystalline alkynyltolan compound, liquid crystal composition and liquid crystal display element | CHISSO CORP (JP) | 1996-11-20 | — | — | CN | disclosed |
| EP-0738709-A2 | Ester derivate, liquid crystal composition and liquid crystal display element | Chisso Corporation (JP) | 1996-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | ALDH1A1 286/4885RXRA 2157/4885RXRB 2226/4885 |
| US-20100105604-A1 | ALLYLOXY AND ALKYLOXY BENZOIC ACID DELIVERY AGENTS | ABCB11, TSPO, AADAC | ALDH1A1 196/4885RXRA 1077/4885RXRB 1865/4885 |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | CYP11B2, CYP11B1, NQO1 | ALDH1A1 374/4885RXRA 1871/4885RXRB 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.